A simple high-performance liquid chromatography assay for simultaneous measurement of adenosine, guanosine, and the oxypurine metabolites in plasma

被引:23
作者
Feng, JDZ
Yeung, PKF [1 ]
机构
[1] Dalhousie Univ, Coll Pharm, Pharmacokinet & Metab Lab, Fac Hlth Profess, Halifax, NS B3H 3J5, Canada
[2] Dalhousie Univ, Fac Hlth Profess, Dept Med, Halifax, NS B3H 3J5, Canada
[3] Dalhousie Univ, Fac Med, Halifax, NS B3H 3J5, Canada
关键词
adenosine; oxypurines; HPLC; plasma; pharmacokinetics;
D O I
10.1097/00007691-200004000-00007
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To study the effect of pharmacologic agents on the biologic fate of adenosine, a reversed-phase high-performance liquid chromatography (HPLC) assay coupled with a solid-phase extraction (SPE) method was developed for simultaneous determination of plasma adenosine, hypoxanthine, xanthine, inosine, guanosine, and uric acid. The HPLC system consisted of a reversed phase C-18 column, UV detector set at 254 nm, and a mobile phase composed of 0.01 M ammonium phosphate: methanol (9.5 : 0.5) vol/vol with the final pH adjusted to 3.9. The standard curves were linear between 0.1-2 mu g/mL for all the analytes (except uric acid 50-400 mu g/mL), with r(2) > 0.99. The absolute recoveries were >60% and accuracy >85% in almost all cases. The limit of detection was <1 ne based on absolute injection of the analytes. The intraassay variations were <10% and interassay variations <15%. The presence of a wide range of medications in plasma samples did not interfere with the assay. The assay was applied successfully to measure plasma adenosine and the oxypurine metabolites in humans and rats. It was noted that plasma concentrations of adenosine and the oxypurine metabolites can vary considerably depending on the method of blood sample collection, and that species differences are apparent.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 30 条
[1]   CA2+ PRECONDITIONING ELICITS A UNIQUE PROTECTION AGAINST THE CA2+ PARADOX INJURY IN RAT-HEART - ROLE OF ADENOSINE [J].
ASHRAF, M ;
SULEIMAN, J ;
AHMAD, M .
CIRCULATION RESEARCH, 1994, 74 (02) :360-367
[2]   THE ROLE OF ADENOSINE IN THE REGULATION OF CORONARY BLOOD-FLOW [J].
BERNE, RM .
CIRCULATION RESEARCH, 1980, 47 (06) :807-813
[3]  
DECKERT J, 1994, J NEURAL TRANSM-SUPP, P23
[4]  
DILORIO P, 1988, PHARMACOL RES COMMUN, V20, P511
[5]   EVALUATION OF THE METABOLIC COMPENSATION AFTER TREADMILL TEST IN PATIENTS WITH PERIPHERAL OCCLUSIVE ARTERIAL-DISEASE [J].
DUPREZ, D ;
DEBUYZERE, M ;
VANWASSENHOVE, A ;
CLEMENT, D .
ANGIOLOGY, 1992, 43 (02) :126-133
[6]   PROTECTIVE EFFECTS OF ADENOSINE IN MYOCARDIAL-ISCHEMIA [J].
ELY, SW ;
BERNE, RM .
CIRCULATION, 1992, 85 (03) :893-904
[7]   ERYTHROCYTE ADENOSINE TRANSPORT - EFFECTS OF CA-2+ CHANNEL ANTAGONISTS AND IONS [J].
FORD, DA ;
SHARP, JA ;
ROVETTO, MJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (05) :H593-H598
[8]  
FREDHOLM BB, 1994, J NEUROCHEM, V62, P563
[9]  
GERLACH E, 1987, FORMATION ADENOSINE, P309
[10]  
GEWIRTZ H, 1987, P SOC EXP BIOL MED, V185, P93